- Case report
- Open Access
Novel complex translocation involving 5 different chromosomes in a chronic myeloid leukemia with Philadelphia chromosome: a case report
© Al Achkar et al; licensee BioMed Central Ltd. 2009
- Received: 14 September 2009
- Accepted: 09 November 2009
- Published: 09 November 2009
The well-known typical fusion gene BCR/ABL can be observed in connection with a complex translocation event in only 2-10% of cases with chronic myeloid leukemia (CML). As currently most CML cases are treated with Imatinib, variant rearrangements have in general no specific prognostic significance, though the emergence of therapy resistance remains to be studied.
Here we report an exceptional CML case with complex chromosomal aberrations not observed before, involving a 5 chromosome translocation implying chromosomal regions such as 1q42, 4p14 and 5q31 besides 9q34 and 22q11.2.
The reported rearrangement developed most probably in one initial step and had no influence on a good response during Imatinib treatment.
- Chronic Myeloid Leukemia
- Clonal Evolution
- Complex Translocation
- Variant Translocation
Chronic myeloid leukemia (CML), a clonal myeloproliferative disease is known to develop from a pluripotent bone-marrow stem cell following the typical BCR and ABL somatic gene rearrangement. In 90-95% of cases with CML, the BCR/ABL fusion gene is the result of reciprocal translocation between chromosomes 9 and 22 and is cytogenetically observable as a small derivative chromosome 22 which is known as Philadelphia (Ph1) chromosome [1, 2].
In a Ph-positive CML expression of the BCR/ABL chimeric protein p210 with an increased tyrosine kinase activity is essential for multiple signaling pathways to confer the leukemia phenotype . Imatinib mesylate (Glivec, formerly STI571) was designed specifically to inhibit the tyrosine kinase activity of the bcr/abl protein and other tyrosine kinases such as c-abl, c-kit and platelet-derived growth factor receptor. By binding to an active site of the tyrosine kinase, Imatinib mesylate switches off downstream signaling, cells stop proliferating and apoptosis ensues . Many studies have shown a high efficiency of Imatinib therapy to achieve a complete or major cytogenetic response, i.e. 0-34% Ph-positive cells. This positive effect may be achieved in cases with simple t(9;22), and complex translocations resulting in a BCR/ABL fusion gene, as well as in cases with cytogenetic clonal evolution [5, 6].
Complex chromosomal rearrangements involving one or more additional chromosomes were described in >600 cases with CML . By conventional cytogenetic analysis, two variant subgroups have traditionally been recognized: complex, t(9;22;V), where V represents a third translocation partner chromosome and simple, t(9;V) or t(22;V) . Only in a few cases is a chromosomal fragment from the third chromosome translocated to the der(22)t(9;22), producing a 'masked Ph' . In most Ph-variant cases the segment 22q11->qter is moved to a third chromosome, while a part of the third chromosome is located on 9q34. Deletions on the derivative chromosome 9 were found to occur with a much higher frequency in patients with variant Ph translocations (45%) than in those with classic Ph (17%) .
Herein we report on a CML cases with new complex aberrations with five chromosomal breakpoints, nonetheless successfully treatable by Imatinib.
The 45 year old female patient presented initially with a whole blood cell count (WBC) of 43.500/l, splenomegaly and severe loss of weight. Chromosome analysis using banding cytogenetics only revealed a karyotype in concordance with the clinical diagnosis of a CML in chronic phase. She was treated with Hydroxyurea (1000 mg daily dose).
Four years and four months later her WBC was 17.61 × 109/l, i.e. 71.6% neutrophils, 18.9% lymphocytes, 3.1% eosinophiles, 5.1% monocytes, 0.2% basophiles. Platelets count was 650 × 109/l and hemoglobin 12.1 g/dl. She was treated with Imatinib (400 mg daily dose) for overall 10 months. Then her WBC was 27.70 × 109/liter, i.e. 70.2% neutrophils, 16.5% lymphocytes, 5.7% eosinophiles, 6.6% monocytes and 0.1% basophiles. Platelets count was 793 × 109/l and hemoglobin 12.7 g/dl. Serum lactate dehydrogenase (LDH) was 515 U/l (normal up to 480 U/l), and serum alkaline phosphates was 120 U/l (normal: up to 90 U/l).
According to the literature, in 2-10% CML cases the fusion gene BCR/ABL is a result of a complex translocation. At present it appears that variant translocations can affect any chromosome. However, it has been suggested that distribution of the break-points is non-random with the chromosomal bands most susceptible to breakage being: 1p36, 3p21, 5q31, 6p21, 9q22, 10q22, 11q13, 12p13, 17p13, 17q21, 17q25, 19q13, 21q22, 22q12 and 22q13 . In our study we found one out of the three breakpoints to be member of this list, i.e. 5q31. However, the fusion gene remained on chromosome 22.
Two possible mechanisms for variant translocation formation were suggested. The first is a single-event rearrangement via the simultaneous breakage of several chromosomes followed by mismatched joining . Nacheva et al proposed a classical Ph translocation followed by a further translocation event between chromosomes 9 and 22 plus a third chromosome . The mechanism of the formation of a variant Ph translocation may have prognostic importance in that a two-event mechanism represents clonal evolution, whereas a variant translocation occurring via a single genomic rearrangement may confer a similar prognosis to the classical Ph translocation; i.e. clonal evolution has a worse prognosis . According to that, we suggest that the reported patient developed the rearrangement in one initial step and thus, also had such a good response to treatment.
Banding cytogenetics using GTG-banding was done according to standard procedures ; 20 metaphases derived from unstimulated bone marrow of the patient were analyzed, each.
Fluorescence in situ hybridization (FISH) using commercially available probes for BCR and ABL (Abbott/Vysis) were applied according to manufacturers instructions. High resolution array-proven multicolor-banding (aMCB) based on microdissection derived region-specific libraries for chromosome 1, 4, 5, 9 and 22 was done as described before; method and MCB probe sets are specified [11, 16]. 20 metaphase spreads were analyzed, each using a fluorescence microscope (AxioImager.Z1 mot, Zeiss) equipped with appropriate filter sets to discriminate between a maximum of five fluorochromes and the counterstain DAPI (Diaminophenylindol). Image capturing and processing were carried out using an Isis mFISH imaging system (MetaSystems, Altlussheim, Germany) for the evaluation MCB.
Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
We would like to thank Prof. Ibrahim Othman, the Director General of Atomic Energy Commission of Syria (AECS), and Dr. Nizar MirAli, Head of Molecular Biology and Biotechnology Department, for their support.
This work was supported by the AECS, in parts by the Stefan-Morsch-Stiftung, Monika-Kutzner-Stiftung and the DAAD (D/07/09624).
- Rooney DE: Human Cytogenetics Malignancy and Acquired Abnormalities. 3rd edition. Oxford University Press, New York; 2001:37.Google Scholar
- Sessions J: Chronic myeloid leukemia in 2007. Am J Health Syst Pharm 2007, 64: S4–9. 10.2146/ajhp070484PubMedView ArticleGoogle Scholar
- Lugo T, Pendergast A, Müller A, Witte O: Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 1990, 247: 1079–1082. 10.1126/science.2408149PubMedView ArticleGoogle Scholar
- Griffen J: The biology of signal transduction The biology of signal transduction inhibition: basic science to novel therapies. Semin Oncol 2001, 28: 3–8.View ArticleGoogle Scholar
- Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C, Niederwieser D, Resta D, Capdeville R, Zoellner U, Talpaz M, Druker B, Goldman J, O'Brien SG, Russell N, Fischer T, Ottmann O, Cony-Makhoul P, Facon T, Stone R, Miller C, Tallman M, Brown R, Schuster M, Loughran T, Gratwohl A, Mandelli F, Saglio G, Lazzarino M, Russo D, Baccarani M, Morra E: Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002, 346: 645–652. 10.1056/NEJMoa011573PubMedView ArticleGoogle Scholar
- Cortes JE, Talpaz M, Giles F, O'Brien S, Rios MB, Shan J, Garcia-Manero G, Faderl S, Thomas DA, Wierda W, Ferrajoli A, Jeha S, Kantarjian HM: Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy. Blood 2003, 101: 3794–3800. 10.1182/blood-2002-09-2790PubMedView ArticleGoogle Scholar
- Johansson B, Fioretos T, Mitelman F: Cytogenetic and molecular genetic evolution of chronic myeloid leukemia. Acta Haematol 2002, 107: 76–94. 10.1159/000046636PubMedView ArticleGoogle Scholar
- Huret JL: Complex translocations, simple variant translocations and Ph-negative cases in chronic myelogenous leukaemia. Hum Genet 1990, 85: 565–568. 10.1007/BF00193575PubMedView ArticleGoogle Scholar
- Hagemeijer A, de Klein A, Godde-Salz E, Turc-Carel C, Smit EME, van Aghtoven AJ, Grosveld GC: Translocation of c-abl to 'masked' Ph in chronic myeloid leukemia. Cancer Genet Cytogenet 1985, 18: 95–104. 10.1016/0165-4608(85)90059-7PubMedView ArticleGoogle Scholar
- Reid A, Gribble SM, Huntly BJ, Andrews KM, Campbell L, Grace CD, Wood ME, Green AR, Nacheva EP: Variant Philadelphia translocations in chronic myeloid leukaemia can mimic typical blast crisis chromosome abnormalities or classic t(9;22): a report of two cases. Br J Haematol 2001, 113: 439–442. 10.1046/j.1365-2141.2001.02778.xPubMedView ArticleGoogle Scholar
- Weise A, Mrasek K, Fickelscher I, Claussen U, Cheung SW, Cai WW, Liehr T, Kosyakova N: Molecular definition of high-resolution multicolor banding probes: first within the human DNA sequence anchored FISH banding probe set. J Histochem Cytochem 2008, 56: 487–493. 10.1369/jhc.2008.950550PubMed CentralPubMedView ArticleGoogle Scholar
- Fitzgerald PH, Morris CM: Complex chromosomal translocations in the Philadelphia chromosome leukemias. Serial translocations or a concerted genomic rearrangement? Cancer Genet Cytogenet 1991, 57: 143–151. 10.1016/0165-4608(91)90145-KPubMedView ArticleGoogle Scholar
- Nacheva E, Holloway T, Brown K, Bloxham D, Green AR: Philadelphia-negative chronic myeloid leukaemia: detection by FISH of BCR-ABL fusion gene localized either to chromosome 9 or chromosome 22. Br J Haematol 1994, 87: 409–412. 10.1111/j.1365-2141.1994.tb04933.xPubMedView ArticleGoogle Scholar
- Reid AG, Huntly BJP, Grace C, Green AR, Nacheva EP: Survival implications of molecular heterogeneity in variant Philadelphia-positive chronic myeloid leukaemia. Br J Haematol 2003, 121: 419–427. 10.1046/j.1365-2141.2003.04291.xPubMedView ArticleGoogle Scholar
- Claussen U, Michel S, Mühlig P, Westermann M, Grummt UW, Kromeyer-Hauschild K, Liehr T: Demystifying chromosome preparation and the implications for the concept of chromosome condensation during mitosis. Cytogenet Genome Res 2002, 98: 136–146. 10.1159/000069817PubMedView ArticleGoogle Scholar
- Liehr T, Heller A, Starke H, Rubtsov N, Trifonov V, Mrasek K, Weise A, Kuechler A, Claussen U: Microdissection based high resolution multicolor banding for all 24 human chromosomes. Int J Mol Med 2002, 9: 335–339.PubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.